Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
Launched by CHINESE UNIVERSITY OF HONG KONG · Nov 18, 2022
Trial Information
Current as of November 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to prevent rebleeding in patients with hepatocellular carcinoma (HCC) who have experienced variceal bleeding (bleeding from swollen veins in the esophagus or stomach). The trial will compare the effectiveness of a new technique called EUS-guided therapy with standard endoscopic treatments, which are currently used to manage this condition. The goal is to see which method better reduces the chances of bleeding again after the initial treatment.
To participate in this study, patients must be 18 years or older and have experienced recent variceal bleeding that was successfully treated with standard methods. They should be able to give their consent to join the trial. Those who cannot give consent, have serious health issues that prevent endoscopy, or are in critical condition due to their illness will not be eligible. Participants can expect close monitoring and care as they receive one of the therapies being studied. This research aims to provide more effective options for managing a challenging condition, potentially improving outcomes for patients with HCC.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Consecutive HCC patients age 18 or older with recent (within 4 weeks of the episode) EV or GV bleeding successfully controlled by conventional endoscopic therapies (VBL for EV or glue injection for GV)
- • Able to provide written informed consent to participate in the study and comply with the study procedures
- Exclusion Criteria:
- • Unable to provide written informed consent
- • Contraindications for endoscopy due to underlying comorbidities
- • HCC patients with non-variceal source of gastrointestinal bleeding
- • Refractory coagulopathy (INR\>1.5) or refractory thrombocytopenia (platelets \<50,000) despite blood product transfusion
- • Moribund patients from terminal illness
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sha Tin, New Territories, Hong Kong
Patients applied
Trial Officials
Raymond S Tang, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials